<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03710707</url>
  </required_header>
  <id_info>
    <org_study_id>DNLI-B-0002</org_study_id>
    <nct_id>NCT03710707</nct_id>
  </id_info>
  <brief_title>Study to Evaluate DNL201 in Subjects With Parkinson's Disease</brief_title>
  <official_title>A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL201 in Subjects With Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Denali Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Denali Therapeutics Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and
      pharmacodynamics of multiple oral doses of DNL201 in subjects with Parkinson's disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 4, 2018</start_date>
  <completion_date type="Actual">December 6, 2019</completion_date>
  <primary_completion_date type="Actual">December 6, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with laboratory test abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with vital sign abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with electrocardiogram (ECG) abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Subjects with clinically significant neurological examination abnormalities</measure>
    <time_frame>Randomization to Day 42</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of maximum observed plasma concentration (Cmax) of DNL201</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of time to reach maximum observed plasma concentration (Tmax) of DNL201</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of trough plasma observed concentration (Ctrough) of DNL201</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of area under the plasma drug concentration-time curve (AUC) of DNL201</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic measure of CSF concentrations of DNL201</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measure of pS935 in whole blood and/or PBMCs</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamic measure of pRab10 in PBMCs</measure>
    <time_frame>Randomization to Day 28</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>DNL201 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>DNL201 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DNL201</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>DNL201 high dose</arm_group_label>
    <arm_group_label>DNL201 low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral repeating dose</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Body mass index (BMI) between 18 and 35.0 kg/m2, inclusive

          -  Clinical diagnosis of Parkinson's disease meeting UK Brain Bank criteria and H&amp;Y Stage
             I, II, or III.

          -  sPD subgroup without a LRRK2 mutation; PD LRRK2 subgroup with LRRK2 mutation

          -  Screening dopamine transporter (DAT) SPECT scan with a DAT deficit consistent with
             Parkinson's disease

          -  Able to hold Parkinson's disease medications 8 hours (overnight) prior to specific
             study assessments

        Key Exclusion Criteria:

          -  Any history of clinically significant asthma, chronic obstructive pulmonary disease,
             or emphysema within 5 years of screening, or other clinically significant pulmonary
             disease within 6 months of screening

          -  Abnormal Vitals including Respiratory Rate, Body Temperature, and Blood Pressure

          -  Pulmonary Function Tests (PFTs) (FVC &lt;60% predicted, FEV1 &lt;50% predicted, FEV1:FVC
             ratio &lt;0.6, DLCO &lt;70% predicted)

          -  Clinically significant neurologic disorder other than Parkinson's disease, including
             history of stroke, cognitive impairment, seizure within 5 years of screening, or head
             trauma with loss of consciousness within 6 months of screening

          -  Montreal Cognitive Assessment (MoCA) score of &lt;24 at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Site(s)</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 15, 2018</study_first_submitted>
  <study_first_submitted_qc>October 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 18, 2018</study_first_posted>
  <last_update_submitted>January 8, 2020</last_update_submitted>
  <last_update_submitted_qc>January 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LRRK2</keyword>
  <keyword>Parkinson's Disease</keyword>
  <keyword>Movement Disorders</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

